PERRIGO Co plc (PRGO)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $15.95
- As of
Kresmion compiles this page from PRGO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PERRIGO Co plc (PRGO): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full PRGO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PRGO on one page. Preview it with sample data, then open it live with a free account.
Preview the PRGO dossierActive signals for PRGO
- highCONSENSUS_BUY
4 tracked funds increased PRGO this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 43.2%, EPS $0.50 vs $0.3492 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +120% to PRGO (2026Q2)
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in PRGO
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 69% of PRGO (2026Q2)
FREE, NO ACCOUNT
Every signal on PRGO, as it fires
You are seeing 5 of 11 signals recorded on PRGO since 2026-05-17.
The five above landed across 3 days. The other 6 were recorded on 2 other days. 7 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PRGO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP G97822103 · 2026Q2 | $31M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP G97822103 · 2026Q2 | $7.4M | 0.01% | , |
| Bridgewater Associates, LPCUSIP G97822103 · 2026Q2 | $3.4M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP G97822103 · 2026Q2 | $2.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP G97822103 · 2026Q2 | $1.3M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP G97822103 · 2026Q2 | $1.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PRGO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PRGO against its peers
PRGO's operating margin of -26.4% ranks in the 18th percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | PRGO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.3B USD | 567M USD | 92 | 18 |
| Revenue YoY | n/a | -4.3% | n/a | 5 |
| Gross margin | 35.1% | 49.8% | 22 | 15 |
| Operating margin | -26.4% | -0.7% | 18 | 18 |
| Net margin | -33.5% | -5.8% | 18 | 19 |
| Return on equity | -48.6% | -8.7% | 9 | 16 |
| 1 year | -26.4% | -17.9% | 38 | 16 |
Peers (21): ALVO, PBH, HCM, CURLF, ETON, GTBIF, RGC, CRON, HROW, INDV, KNSA, AQST, EOLS, TLRY, VREOF, KMDA, NIKA, TKNO, VRNO, ELAN, CGC. Left out: HYPMY (no annual filing), EVO (period gap), RDY (period gap), BORAY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PRGO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PRGO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PRGO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.